Tags

Type your tag names separated by a space and hit enter

Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses.
J Immunol. 2012 Aug 15; 189(4):1983-91.JI

Abstract

Asthma is a disease of airway inflammation that in most cases fails to resolve. The resolution of inflammation is an active process governed by specific chemical mediators, including D-series resolvins. In this study, we determined the impact of resolvin D1 (RvD1) and aspirin-triggered RvD1 (AT-RvD1) on the development of allergic airway responses and their resolution. Mice were allergen sensitized, and RvD1, AT-RvD1 (1, 10, or 100 ng), or vehicle was administered at select intervals before or after aerosol allergen challenge. RvD1 markedly decreased airway eosinophilia and mucus metaplasia, in part by decreasing IL-5 and IκBα degradation. For the resolution of established allergic airway responses, AT-RvD1 was even more efficacious than RvD1, leading to a marked decrease in the resolution interval for lung eosinophilia, decrements in select inflammatory peptide and lipid mediators, and more rapid resolution of airway hyperreactivity to methacholine. Relative to RvD1, AT-RvD1 resisted metabolic inactivation by macrophages, and AT-RvD1 significantly enhanced macrophage phagocytosis of IgG-OVA-coated beads in vitro and in vivo, a new proresolving mechanism for the clearance of allergen from the airways. In conclusion, RvD1 and AT-RvD1 can serve as important modulators of allergic airway responses by decreasing eosinophils and proinflammatory mediators and promoting macrophage clearance of allergen. Together, these findings identify D-series resolvins as potential proresolving therapeutic agents for allergic responses.

Authors+Show Affiliations

Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22802419

Citation

Rogerio, Alexandre P., et al. "Resolvin D1 and Aspirin-triggered Resolvin D1 Promote Resolution of Allergic Airways Responses." Journal of Immunology (Baltimore, Md. : 1950), vol. 189, no. 4, 2012, pp. 1983-91.
Rogerio AP, Haworth O, Croze R, et al. Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. J Immunol. 2012;189(4):1983-91.
Rogerio, A. P., Haworth, O., Croze, R., Oh, S. F., Uddin, M., Carlo, T., Pfeffer, M. A., Priluck, R., Serhan, C. N., & Levy, B. D. (2012). Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. Journal of Immunology (Baltimore, Md. : 1950), 189(4), 1983-91. https://doi.org/10.4049/jimmunol.1101665
Rogerio AP, et al. Resolvin D1 and Aspirin-triggered Resolvin D1 Promote Resolution of Allergic Airways Responses. J Immunol. 2012 Aug 15;189(4):1983-91. PubMed PMID: 22802419.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. AU - Rogerio,Alexandre P, AU - Haworth,Oliver, AU - Croze,Roxanne, AU - Oh,Sungwhan F, AU - Uddin,Mohib, AU - Carlo,Troy, AU - Pfeffer,Michael A, AU - Priluck,Rebekah, AU - Serhan,Charles N, AU - Levy,Bruce D, Y1 - 2012/07/16/ PY - 2012/7/18/entrez PY - 2012/7/18/pubmed PY - 2012/10/20/medline SP - 1983 EP - 91 JF - Journal of immunology (Baltimore, Md. : 1950) JO - J Immunol VL - 189 IS - 4 N2 - Asthma is a disease of airway inflammation that in most cases fails to resolve. The resolution of inflammation is an active process governed by specific chemical mediators, including D-series resolvins. In this study, we determined the impact of resolvin D1 (RvD1) and aspirin-triggered RvD1 (AT-RvD1) on the development of allergic airway responses and their resolution. Mice were allergen sensitized, and RvD1, AT-RvD1 (1, 10, or 100 ng), or vehicle was administered at select intervals before or after aerosol allergen challenge. RvD1 markedly decreased airway eosinophilia and mucus metaplasia, in part by decreasing IL-5 and IκBα degradation. For the resolution of established allergic airway responses, AT-RvD1 was even more efficacious than RvD1, leading to a marked decrease in the resolution interval for lung eosinophilia, decrements in select inflammatory peptide and lipid mediators, and more rapid resolution of airway hyperreactivity to methacholine. Relative to RvD1, AT-RvD1 resisted metabolic inactivation by macrophages, and AT-RvD1 significantly enhanced macrophage phagocytosis of IgG-OVA-coated beads in vitro and in vivo, a new proresolving mechanism for the clearance of allergen from the airways. In conclusion, RvD1 and AT-RvD1 can serve as important modulators of allergic airway responses by decreasing eosinophils and proinflammatory mediators and promoting macrophage clearance of allergen. Together, these findings identify D-series resolvins as potential proresolving therapeutic agents for allergic responses. SN - 1550-6606 UR - https://www.unboundmedicine.com/medline/citation/22802419/Resolvin_D1_and_aspirin_triggered_resolvin_D1_promote_resolution_of_allergic_airways_responses_ L2 - http://www.jimmunol.org/cgi/pmidlookup?view=long&pmid=22802419 DB - PRIME DP - Unbound Medicine ER -